Trial Profile
Study to detect safety and efficacy of switch from standard-release tacrolimus (prograf) to extended-release tacrolimus (advagraf) in chronic heart transplant patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2015
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 11 Aug 2015 New trial record